# OnCo record da-trial-trailblazer-alz2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/da-trial-trailblazer-alz2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "da-trial-trailblazer-alz2", "NCT04437511" ;
  schema:name "TRAILBLAZER-ALZ 2"@en ;
  schema:description "TRAILBLAZER-ALZ 2 tested donanemab in early Alzheimer’s disease and is the main efficacy trial behind the US approval."@en ;
  schema:url <https://onco.cc/trials/da-trial-trailblazer-alz2/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04437511>, <https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease> ;
  onco:status "completed" ;
  onco:tag "dementia-atlas" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/diagnoses/alzheimers-disease/> ;
  onco:drugs <https://onco.cc/drugs/da-donanemab/> ;
  onco:companies <https://onco.cc/companies/da-lilly/> .